Category: Oncotarget

Oncotarget News

Oncotarget

Oncotarget | Targeting Krebs-cycle-deficient RCC with Poly ADP-ribose Polymerase Inhibitors, Low-dose Alkylating Chemotherapy

September 20, 2022

In this study, we sought to examine the activity of combined TMZ and PARPi in Krebs-cycle-deficient renal cancer models.”BUFFALO, NY- September 20, 2022 – A new research paper was published... read more

Oncotarget

Behind the Study: Inhibition of Resistant Triple-negative Breast Cancer Cells

September 19, 2022

Dr. Balraj Singh from the University of Texas MD Anderson Cancer Center, describes a recent research paper he co-authored that was published by Oncotarget, entitled, “Inhibition of resistant triple-negative breast... read more

Oncotarget

Oncotarget | An ABC Transporter as Potential Target Against SHH-Medulloblastoma: From Benchtop to Bedside

September 15, 2022

The discovery of novel modulators of the SHH pathway to advance SHH-MB treatment is greatly needed.”BUFFALO, NY- September 15, 2022 – A new editorial paper was published in Oncotarget on... read more

Dr. Glenn Simmons Jr. and Dr. Stefani Thomas

Oncotarget

Behind the Study: Targeting Lipid Metabolism in Treatment of Ovarian Cancer

September 12, 2022

Dr. Glenn Simmons Jr. from Cornell University College of Veterinary Medicine, and Dr. Stefani Thomas from University of Minnesota School of Medicine, detail a recent review they co-authored that was... read more

Oncotarget

Oncotarget | Targeted Elastin-like Polypeptide Fusion Protein for Near-infrared Imaging of Human and Canine Urothelial Carcinoma

September 8, 2022

We have developed a peptide-based NIR probe, Cy5.5-N24-EGF, that shows high EGFR-specific binding specificity in canine and human UC in vitro and ex vivo.”BUFFALO, NY- September 8, 2022 –... read more

Oncotarget

Oncotarget | Kinase Activity in Renal Cell Carcinoma, Benign Renal Tissue and in Response to Tyrosine Kinase Inhibitors

August 17, 2022

Thus, the presented findings might provide options to select the most promising TKI for individual RCC patients prior to initiation of TKI-therapies.”BUFFALO, NY- August 17, 2022 – A new research... read more

Oncotarget

Oncotarget | Glypican-3 (GPC3) Associated With MCPyV-negative Status and Impaired Outcome in Merkel Cell Carcinoma

August 11, 2022

High prevalence of surface GPC3 makes it a putative drug target.”BUFFALO, NY- August 11, 2022 – A new research paper was published in Oncotarget on August 3,... read more

Oncotarget

Oncotarget | A Novel Mechanism of Regulation of the Oncogenic Transcription Factor GLI3 by Toll-like Receptor Signaling

August 9, 2022

These results increase our understanding of the signaling molecules that can regulate GLI3 in a HH-independent manner.”BUFFALO, NY- August 9, 2022 – A new research paper was published in Oncotarget... read more

Oncotarget

Oncotarget | Chemoradiation Alters PD-L1, CD8+ TILs and Mucin in Rectal Cancer

August 2, 2022

In conclusion, our study provides further data on the immunologic impact of nCRT in rectal cancer.”BUFFALO, NY- August 2, 2022 – A new research paper was published in ... read more

Oncotarget

Oncotarget | CUDC907 Promotes Apoptosis of NF2 Schwannoma Cells

July 26, 2022

CUDC907 has cytotoxic activity in NF2 schwannoma models and primary VS cells and is a candidate for clinical trials.”BUFFALO, NY- July 26, 2022 – A new research paper was... read more